Home › Funds › PSP Research LLC › ACAD

PSP Research LLC position in ACAD

ACADIA PHARMACEUTICALS INC · Health Care

PSP Research LLC reported holding 19,766 shares of ACAD (ACADIA PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$500K, representing 0.27% of its reported portfolio and ranking #20 among its reported holdings. PSP Research LLC has disclosed ACAD holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)19.77K sh
Reported value held$500.08K
Portfolio Weight0.27%
First reportedQ4 2025
Last changeNew

How PSP Research LLC's ACAD position evolved

PSP Research LLC first disclosed a stake in ACAD in Q4 2025 at 19,766 shares (US$528K). Across 3 filings, PSP Research LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 19,766 shares valued at US$500K.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 19.77K $527.95K New
Q1 2026 19.77K $439.99K Hold
Q2 2026 19.77K $500.08K New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ACAD and 13F data

ACAD (ACADIA PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in ACAD — the largest reported positions include BAKER BROS. ADVISORS LP (US$1.09B), RTW INVESTMENTS, LP (US$180.8M), Palo Alto Investors LP (US$72.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ACAD

All ACAD fund holders →